A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastati

A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation is a phase 3, interventional study registered as NCT07809256 by EuroCityClinic LLC, with a registry enrolment figure of 15 participants, started 2026-09 and due to reach its primary completion in 2028-08. Interventions recorded: lenvatinib pembrolizumab. Conditions listed: NSCLC (Non-small Cell Lung Cancer)R. Primary outcome: Progression-Free Survival (PFS); Objective Response Rate (ORR); Disease Control Rate (DCR). Lung eligibility wording from the registry: "Have a confirmed diagnosis of metastatic non-small cell lung cancer (NSCLC), established by examination of a tumor tissue sample, with cancer that has spread to distant parts of the body". Sites: Russia. No results are recorded here; the registry entry is the source.